Yesterday, MEI Pharma announced that it has appointed Thomas C. Reynolds, M.D., Ph.D., to its Board of Directors. An industry veteran, Dr. Reynolds brings over 20 years of oncology drug development experience to MEI, including direct oversight in the development and approval of the hematologic cancer drug ADCETRIS.

“I am delighted to join the Board of MEI Pharma at such an exciting time for the company,” said Dr. Reynolds. “I believe that MEI Pharma is poised to make an immediate impact in the oncology arena with its lead drug candidate, Pracinostat. I look forward to working closely with the rest of the Board and management team to execute the optimal clinical development and marketing approval strategy for Pracinostat and ultimately realize its significant potential.”

Dr. Reynolds served as Chief Medical Officer of Seattle Genetics from March 2007 until retiring in February 2013. While at Seattle Genetics, he built and led an integrated clinical development, regulatory, and medical affairs organization, highlighted by the development and approval of ADCETRIS. ADCETRIS is an antibody-drug conjugate approved to treat anaplastic large cell lymphoma and Hodgkin’s lymphoma.

Previously, Dr. Reynolds served at ZymoGenetics in the position of Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM. Prior to joining ZymoGenetics, he was Vice President, Clinical Affairs at Targeted Genetics. Dr. Reynolds received his M.D. and Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.

MEI’s President and CEO, Daniel P. Gold, remarked, “Dr. Reynolds’ proven drug development expertise and valuable industry perspective make him a welcome addition to our Board. His appointment is particularly timely as we prepare for the expansion of our clinical development program for Pracinostat in the months ahead.”

For more information, visit www.meipharma.com

Let us hear your thoughts below: